Literature DB >> 23254204

Mortality in a cohort of young primary cocaine users: controlling the effect of the riskiest drug-use behaviors.

Gregorio Barrio1, Gemma Molist, Luis de la Fuente, Fermín Fernández, Anna Guitart, María J Bravo, M Teresa Brugal.   

Abstract

BACKGROUND: Published studies indicate that primary cocaine users (PCUs) have a mortality rate 4-8 times higher than their age-sex peers in the general population. Most PCUs are primary intranasal cocaine users, never-injectors and never-opioid users (PICUNINOs) and are usually underrepresented in cohort mortality studies. The aim is to estimate excess mortality in all PCUs and in the subgroups of never-opioid users and PICUNINOs in Spain.
METHODS: 714 PCUs aged 18-30 were street-recruited in 2004-2006 in Spain and followed until 2010 to ascertain vital status. Drug use was self-reported at baseline and 1-2years later. Mortality was compared with that of the general population using standardized mortality ratios (SMRs).
RESULTS: SMRs were 4.7 (95% CI: 2.4-9.0), 2.5 (95%CI: 0.8-7.8) and 3.1 (95% CI: 1.0-9.6), respectively, among all participants, never-opioid users and PICUNINOS when using only baseline data on drug use, and 1.2 (95% CI: 0.2-8.5) and 1.4 (95% CI: 0.2-9.9) among the latter two subgroups, when using baseline plus follow-up data.
CONCLUSION: Short-term mortality in young Spanish PCUs is 5 times higher than in the general population. This excess mortality may largely be explained by a history of opioid use or the risk of starting such use.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23254204     DOI: 10.1016/j.addbeh.2012.10.007

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  7 in total

1.  Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders.

Authors:  Adriane M Dela Cruz; Thomas Carmody; Tracy L Greer; Chad D Rethorst; Diane Warden; Robrina Walker; Madhukar H Trivedi
Journal:  Am J Addict       Date:  2016-03-15

Review 2.  Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence.

Authors:  Kenneth M Dürsteler; Eva-Maria Berger; Johannes Strasser; Carlo Caflisch; Jochen Mutschler; Marcus Herdener; Marc Vogel
Journal:  Subst Abuse Rehabil       Date:  2015-06-17

3.  The impact of drug use patterns on mortality among polysubstance users in a Canadian setting: a prospective cohort study.

Authors:  Anna Hayden; Kanna Hayashi; Huiru Dong; Michael-John Milloy; Thomas Kerr; Julio S G Montaner; Evan Wood
Journal:  BMC Public Health       Date:  2014-11-06       Impact factor: 3.295

Review 4.  All-cause and cause-specific mortality among people with regular or problematic cocaine use: a systematic review and meta-analysis.

Authors:  Amy Peacock; Lucy Thi Tran; Sarah Larney; Emily Stockings; Thomas Santo; Hayley Jones; Damian Santomauro; Louisa Degenhardt
Journal:  Addiction       Date:  2020-09-21       Impact factor: 6.526

5.  Gender differences in mortality and risk factors in a 13-year cohort study of street-recruited injecting drug users.

Authors:  Linn Gjersing; Anne Line Bretteville-Jensen
Journal:  BMC Public Health       Date:  2014-05-10       Impact factor: 3.295

6.  Impact of Cocaine Use on Acute Ischemic Stroke Patients: Insights from Nationwide Inpatient Sample in the United States.

Authors:  Rupak Desai; Upenkumar Patel; Chintan Rupareliya; Sandeep Singh; Manan Shah; Rikinkumar S Patel; Smit Patel; Zabeen Mahuwala
Journal:  Cureus       Date:  2017-08-02

Review 7.  Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis.

Authors:  Robert W Aldridge; Alistair Story; Stephen W Hwang; Merete Nordentoft; Serena A Luchenski; Greg Hartwell; Emily J Tweed; Dan Lewer; Srinivasa Vittal Katikireddi; Andrew C Hayward
Journal:  Lancet       Date:  2017-11-12       Impact factor: 79.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.